New genomic tests continue to be introduced, and in this segment, Peter Salgo, MD, and John L. Fox, MD, MHA, discuss the clinical utility of genomic tests and explore data from key trials that evaluated the validity of current genomic tests.
Dr Fox explains that when reviewing clinical utility it is important to assess whether or not the new information has an impact on decision making and overall clinical outcomes. Dr Fox adds that the MammaPrint, OncoType DX, and PAM50 genomic assays have all demonstrated clinical utility in breast cancer. When asked about the validity of a newer breast cancer assay, Prosigna, Dr Fox discusses the TransATAC trial and explains that results are inconclusive due to a stratification advantage.
Ultimately, all stakeholders involved in patient care want to have a clear understanding of available diagnostic tests. The goal is to use the test results to make informed decisions and allow each patient to receive the treatment that is most appropriate for his or her condition.
Watch our related Peer Exchange, Oncology Stakeholder Summit 2014: Evidence-Based Decisions to Improve Quality and Regulate Costs
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Uniting to Support Patients With Cancer Beyond Treatment
November 17th 2024Kasey Bond, MPH, of Perlmutter Cancer Center at NYU Langone Health, speaks to why it’s vital to keep patients at the center of all strategic partnerships between academic institutions and community-based oncology practices.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Bridging Cancer Care Gaps and Overcoming Medical Mistrust
November 13th 2024In this clip from our interview with Oscar B. Lahoud, MD, cochair of our Institute for Value-Based Medicine® evening hosted with NYU Langone Health, he addressed medical mistrust in underrepresented communities.
Read More
How English- and Spanish-Preferring Patients With Cancer Decide on Emergency Care
November 13th 2024Care delivery innovations to help patients with cancer avoid emergency department visits are underused. The authors interviewed English- and Spanish-preferring patients at 2 diverse health systems to understand why.
Read More